Beyond aspirin—cancer prevention with statins, metformin and bisphosphonates

[1]  Chieh-Hsi Wu,et al.  A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia , 2015, Clinical endocrinology.

[2]  M. Brandi,et al.  Pharmacogenetics of osteoporosis. , 2014, Best practice & research. Clinical endocrinology & metabolism.

[3]  Liu Yun-qia.  Metformin and cancer risk in diabetic patients , 2014 .

[4]  I. Beales,et al.  Statin use is associated with a reduction in the incidence of esophageal adenocarcinoma: a case control study. , 2013, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[5]  A. LaCroix,et al.  Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  Cheng Lu,et al.  Exposure to bisphosphonates and risk of colorectal cancer. , 2013, British journal of clinical pharmacology.

[7]  L. Mariani,et al.  Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2013, PloS one.

[8]  Samy Suissa,et al.  Response to Yang and Chan. Metformin and the Risk of Cancer: Time-Related Biases in Observational Studies. Diabetes Care 2012;35:2665–2673 , 2013, Diabetes Care.

[9]  S. Gapstur,et al.  Type 2 diabetes mellitus, insulin‐use and risk of bladder cancer in a large cohort study , 2013, International journal of cancer.

[10]  A. Vicente,et al.  Architecture of the superintegron in Vibrio cholerae: identification of core and unique genes , 2013, F1000Research.

[11]  Harminder Singh,et al.  Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Forbes,et al.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Murad,et al.  Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. , 2013, Gastroenterology.

[14]  E. Kopel,et al.  Statin use and reduced cancer-related mortality. , 2013, The New England journal of medicine.

[15]  I. Beales,et al.  Statin use is associated with a reduced incidence of colorectal adenomatous polyps , 2013, International Journal of Colorectal Disease.

[16]  S. Suissa,et al.  The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[17]  B. Dunn,et al.  Future directions in cancer prevention , 2012, Nature Reviews Cancer.

[18]  R. Buckanovich,et al.  Metformin targets ovarian cancer stem cells in vitro and in vivo. , 2012, Gynecologic oncology.

[19]  S. Jick,et al.  Metformin does not alter the risk of lung cancer: a case-control analysis. , 2012, Lung cancer.

[20]  V. Steele,et al.  Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL‐KrasG12D/+ mice , 2012, International journal of cancer.

[21]  P. Almgren,et al.  Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. , 2012, JAMA.

[22]  M Smans,et al.  Diabetes and breast cancer risk: a meta-analysis , 2012, British Journal of Cancer.

[23]  Y. Ben-Shlomo,et al.  Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women , 2012, Cancer Causes & Control.

[24]  S. Ogino,et al.  A prospective study of bisphosphonate use and risk of colorectal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Tzeng-Ji Chen,et al.  Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  C. Abnet,et al.  Exposure to oral bisphosphonates and risk of cancer , 2012, International journal of cancer.

[27]  P. Goodwin,et al.  Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study , 2012, Breast Cancer Research and Treatment.

[28]  Jure Acimovic,et al.  The anti-carcinogenic effect of statins in a rat model correlates with levels and synthesis of ubiquinone. , 2012, Biochemical and biophysical research communications.

[29]  W. Park,et al.  A statin-regulated microRNA represses human c-Myc expression and function , 2012, EMBO molecular medicine.

[30]  F. Hu,et al.  Bisphosphonate use and the risk of breast cancer: a meta-analysis of published literature. , 2012, Clinical breast cancer.

[31]  Nananda F. Col,et al.  Metformin and breast cancer risk: a meta-analysis and critical literature review , 2012, Breast Cancer Research and Treatment.

[32]  K. Rufibach,et al.  Statins and the Risk of Cancer After Heart Transplantation , 2012, Circulation.

[33]  A. Luini,et al.  Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  E. Perez,et al.  Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. , 2012, The Lancet. Oncology.

[35]  Juhua Luo,et al.  Diabetes and Lung Cancer Among Postmenopausal Women , 2012, Diabetes Care.

[36]  J. Manson,et al.  Diabetes, metformin, and breast cancer in postmenopausal women. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Aft,et al.  Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer , 2012, British Journal of Cancer.

[38]  B. Jiang,et al.  Statin use and risk of pancreatic cancer: a meta-analysis , 2012, Cancer Causes & Control.

[39]  M. Thun,et al.  The role of aspirin in cancer prevention , 2012, Nature Reviews Clinical Oncology.

[40]  I. Beales,et al.  Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case–control study , 2012, BMC Gastroenterology.

[41]  Daniel L. Koller,et al.  Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture , 2012, Nature Genetics.

[42]  B. Carstensen,et al.  Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence , 2012, Diabetologia.

[43]  P. Ridker,et al.  Genetic Determinants of Statin-Induced Low-Density Lipoprotein Cholesterol Reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial , 2012, Circulation. Cardiovascular genetics.

[44]  S. Jick,et al.  Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis , 2012, The American Journal of Gastroenterology.

[45]  R. Marais,et al.  Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. , 2012, Cancer discovery.

[46]  Hirokazu Takahashi,et al.  Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial , 2012, BMC Cancer.

[47]  Tetsuro Tsujimoto,et al.  Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis , 2012, PloS one.

[48]  A. Segura‐Carretero,et al.  Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205 , 2012, Cell cycle.

[49]  R. Eastell,et al.  Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate—Danish National Register Based Cohort Study , 2012, Osteoporosis International.

[50]  Yu-Tse Tsan,et al.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Choueiri,et al.  Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts , 2012, Cancer.

[52]  A. Levine,et al.  Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.

[53]  A. Thor,et al.  Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers , 2012, Cell cycle.

[54]  Patricia L. Blount,et al.  Use of Statin Medications and Risk of Esophageal Adenocarcinoma in Persons with Barrett's Esophagus , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[55]  P. Muti,et al.  Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC , 2012, Nature Communications.

[56]  A. Malfitano,et al.  Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer , 2012, Pharmacological Reviews.

[57]  W. Tereffe.  Statin prescriptions and breast cancer recurrence risk: A Danish nationwide prospective cohort study , 2012 .

[58]  D. Výbohová,et al.  Immunohistochemical and histomorphological analysis of rat mammary tumors after simvastatin treatment. , 2012, Neoplasma.

[59]  J. Cauley,et al.  Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. , 2012, Annals of epidemiology.

[60]  A. Tenesa,et al.  Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage , 2012, BMC Cancer.

[61]  M. Dowsett,et al.  A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer , 2012, Breast Cancer Research and Treatment.

[62]  Chun-Yuh Yang,et al.  Statin use and the risk of colorectal cancer: a population-based case-control study. , 2011, World journal of gastroenterology.

[63]  S. Jick,et al.  Use of Metformin Is Not Associated with a Decreased Risk of Colorectal Cancer: A Case–Control Analysis , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[64]  R. Collins,et al.  Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial , 2011 .

[65]  Genevieve M. Monsees,et al.  Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. , 2011, Journal of the National Cancer Institute.

[66]  S. Leal,et al.  Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. , 2011, Atherosclerosis.

[67]  Chun-Yuh Yang,et al.  Statins Are Associated With a Reduced Risk of Gastric Cancer: A Population-Based Case–Control Study , 2011, The American Journal of Gastroenterology.

[68]  E. Kuipers,et al.  Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. , 2011, Gastroenterology.

[69]  J. Meyerhardt,et al.  Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. , 2011, Journal of the National Cancer Institute.

[70]  W. Gregory,et al.  Breast-cancer adjuvant therapy with zoledronic acid. , 2011, The New England journal of medicine.

[71]  J. Hippisley-Cox,et al.  Exposure to statins and risk of common cancers: a series of nested case-control studies , 2011, BMC Cancer.

[72]  H. Kan,et al.  Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 Diabetes , 2011, Diabetes Care.

[73]  A. DeMaria,et al.  Statins and risk of cancer: a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. , 2011, Journal of the American College of Cardiology.

[74]  V. Steele,et al.  Combination of Atorvastatin with Sulindac or Naproxen Profoundly Inhibits Colonic Adenocarcinomas by Suppressing the p65/β-Catenin/Cyclin D1 Signaling Pathway in Rats , 2011, Cancer Prevention Research.

[75]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. , 2011, The Lancet. Oncology.

[76]  I. Ben-Sahra,et al.  Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. , 2011, Cancer research.

[77]  E. Giovannucci,et al.  Statin Use and Colorectal Cancer Risk According to Molecular Subtypes in Two Large Prospective Cohort Studies , 2011, Cancer Prevention Research.

[78]  L. Pusztai,et al.  Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial , 2011, Breast Cancer Research and Treatment.

[79]  Shailendra Giri,et al.  Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. , 2011, Neoplasia.

[80]  Jack Cuzick,et al.  Preventive therapy for breast cancer: a consensus statement. , 2011, The Lancet. Oncology.

[81]  Chun-Yuh Yang,et al.  Statin Use and the Risk of Liver Cancer: A Population-Based Case–Control Study , 2011, The American Journal of Gastroenterology.

[82]  S. Gruber,et al.  Risk of colorectal cancer in self‐reported inflammatory bowel disease and modification of risk by statin and NSAID use , 2011, Cancer.

[83]  B. Martín-Castillo,et al.  Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a , 2011, Cell cycle.

[84]  Yongxian Zhuang,et al.  Metformin Induces Both Caspase-Dependent and Poly(ADP-ribose) Polymerase-Dependent Cell Death in Breast Cancer Cells , 2011, Molecular Cancer Research.

[85]  S. Gruber,et al.  Use of bisphosphonates and reduced risk of colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  S. Gambhir,et al.  MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. , 2011, Cancer research.

[87]  Samy Suissa,et al.  Time-window bias in case-control studies: statins and lung cancer. , 2011, Epidemiology.

[88]  A. Goc,et al.  Anticancer Efficacy of Simvastatin on Prostate Cancer Cells and Tumor Xenografts Is Associated with Inhibition of Akt and Reduced Prostate-Specific Antigen Expression , 2011, Journal of Pharmacology and Experimental Therapeutics.

[89]  Peter Donnelly,et al.  Edinburgh Research Explorer Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes , 2022 .

[90]  M. Thun,et al.  Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. , 2010, Cancer research.

[91]  Tsuyoshi Saito,et al.  Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. , 2010, Oncology reports.

[92]  Hua Li,et al.  Prostate cancer gene expression signature of patients with high body mass index , 2010, Prostate Cancer and Prostatic Diseases.

[93]  I. Holen,et al.  The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells , 2009, Journal of cellular and molecular medicine.

[94]  C. Lawton.  Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer , 2011 .

[95]  F. Esteva.  Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer , 2011 .

[96]  H. Sørensen,et al.  Neither long-term statin use nor atherosclerotic disease is associated with risk of colorectal cancer. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[97]  H. Sørensen,et al.  Metformin and Incident Breast Cancer among Diabetic Women: A Population-Based Case–Control Study in Denmark , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[98]  G. Friedman,et al.  Lipophilic Statin Use and Risk of Breast Cancer Subtypes , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[99]  S. Lipkin,et al.  Clinical genetics of hereditary colorectal cancer. , 2010, Hematology/oncology clinics of North America.

[100]  T. Satou,et al.  Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway , 2010, Journal of experimental & clinical cancer research : CR.

[101]  Gabriela Czanner,et al.  Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort , 2010, BMJ : British Medical Journal.

[102]  Hirokazu Takahashi,et al.  Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial , 2010, Cancer Prevention Research.

[103]  R. Memmott,et al.  Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis , 2010, Cancer Prevention Research.

[104]  B. Stricker,et al.  Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. , 2010, Pharmacogenomics.

[105]  L. Murray,et al.  Statins and pancreatic cancer risk: a nested case–control study , 2010, Cancer Causes & Control.

[106]  P. Boutros,et al.  Dysregulation of the mevalonate pathway promotes transformation , 2010, Proceedings of the National Academy of Sciences.

[107]  J. Manson,et al.  Oral bisphosphonate use and breast cancer incidence in postmenopausal women. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  D. Harlan,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[109]  P. Home,et al.  Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials , 2010, Diabetologia.

[110]  Peter J. Richardson,et al.  Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. , 2010, Gastroenterology.

[111]  N. Samani,et al.  Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction: The GEOSTAT-1 Study , 2010, Circulation. Cardiovascular genetics.

[112]  M. Ellis,et al.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. , 2010, The Lancet. Oncology.

[113]  S. Gruber,et al.  A case-control study of levothyroxine and the risk of colorectal cancer. , 2010, Journal of the National Cancer Institute.

[114]  A. Zauber,et al.  Statin Use and Colorectal Adenoma Risk: Results from the Adenoma Prevention with Celecoxib Trial , 2010, Cancer Prevention Research.

[115]  Stephen B Gruber,et al.  Genetic Variation in 3-Hydroxy-3-Methylglutaryl CoA Reductase Modifies the Chemopreventive Activity of Statins for Colorectal Cancer , 2010, Cancer Prevention Research.

[116]  Manal M. Hassan,et al.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma , 2010, Cancer.

[117]  Jure Acimovic,et al.  Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. , 2010, Anticancer research.

[118]  R E Coleman,et al.  The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer , 2010, British Journal of Cancer.

[119]  A. Trentham-Dietz,et al.  Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk , 2010, British Journal of Cancer.

[120]  G. Rennert,et al.  Use of bisphosphonates and risk of postmenopausal breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  P. Musiani,et al.  Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway , 2009, Journal of cellular and molecular medicine.

[122]  Y. Yen,et al.  Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells , 2010, International journal of cancer.

[123]  J. Lonnqvist,et al.  Incidence of cancer and statin usage—Record linkage study , 2010, International journal of cancer.

[124]  Kevin Struhl,et al.  Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.

[125]  Manal M. Hassan,et al.  Antidiabetic therapies affect risk of pancreatic cancer. , 2009, Gastroenterology.

[126]  Funda Meric-Bernstam,et al.  Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  E. Gale,et al.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.

[128]  P. Donnan,et al.  New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.

[129]  P. Dong,et al.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer. , 2009, The New England journal of medicine.

[130]  J. Menéndez,et al.  Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells , 2009, Cell cycle.

[131]  Michael L. Johnson,et al.  Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. , 2009, Gastroenterology.

[132]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[133]  Michael L. Johnson,et al.  Statins and the Risk of Colorectal Carcinoma: A Nested Case–Control Study in Veterans With Diabetes , 2009, The American Journal of Gastroenterology.

[134]  S. Khosla,et al.  DISORDERS OF CALCIUM METABOLISM AND BONE MINERALIZATION , 2009 .

[135]  安田 考志.  Anti-gout agent allopurinol exerts cytotoxicity to human hormone-refractory prostate cancer cells in combination with tumor necrosis factor-related apoptosis-inducing ligand , 2009 .

[136]  R. Hubbard,et al.  Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. , 2009, British journal of clinical pharmacology.

[137]  D. Miglioretti,et al.  Statin use and female reproductive organ cancer risk in a large population-based setting , 2009, Cancer Causes & Control.

[138]  Alastair M. Thompson,et al.  Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer model , 2009, Breast Cancer Research and Treatment.

[139]  A. Terzic,et al.  Pharmacology and Therapeutics: Principles to Practice , 2008 .

[140]  F. Schuetz,et al.  Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[141]  E. Pukkala,et al.  Statins and cancer: A systematic review and meta-analysis. , 2008, European journal of cancer.

[142]  Nahum Sonenberg,et al.  The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase , 2008, Cancer Prevention Research.

[143]  J. Lewis,et al.  Chronic statin therapy and the risk of colorectal cancer , 2008, Pharmacoepidemiology and drug safety.

[144]  M. Pollak,et al.  Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. , 2008, Endocrine-related cancer.

[145]  In Sung Song,et al.  Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis‐associated colon cancer in mice , 2008, International journal of cancer.

[146]  B. Wells,et al.  Statins and cancer: a meta-analysis of case–control studies , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[147]  H. Gbelcová,et al.  Differences in antitumor effects of various statins on human pancreatic cancer , 2008, International journal of cancer.

[148]  Hung-Ming Wang,et al.  Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. , 2008, Lung cancer.

[149]  J. Gaziano,et al.  The association between statins and cancer incidence in a veterans population. , 2008, Journal of the National Cancer Institute.

[150]  J. Bergh,et al.  Bisphosphonate treatment in primary breast cancer: Results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer , 2008, Acta oncologica.

[151]  G. Friedman,et al.  Screening statins for possible carcinogenic risk: up to 9 years of follow‐up of 361 859 recipients , 2008, Pharmacoepidemiology and drug safety.

[152]  C. Agrati,et al.  In vivo effects of zoledronic acid on peripheral γδ T lymphocytes in early breast cancer patients , 2008, Cancer Immunology and Immunotherapy.

[153]  M. Mi,et al.  BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. , 2008, International journal of oncology.

[154]  L. Habel,et al.  Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors , 2008, Breast Cancer Research and Treatment.

[155]  Z. Werb,et al.  Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. , 2007, Cancer research.

[156]  A. Keeton,et al.  Insulin regulation of growth hormone receptor gene expression: involvement of both the PI-3 kinase and MEK/ERK signaling pathways , 2007, Endocrine.

[157]  D. Hommes,et al.  The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. , 2007, Gastroenterology.

[158]  Hermann Brenner,et al.  Individual and joint use of statins and low‐dose aspirin and risk of colorectal cancer: A population‐based case–control study , 2007, International journal of cancer.

[159]  S. Bonovas,et al.  Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  J. Hippisley-Cox,et al.  Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. , 2007, Gastroenterology.

[161]  M. Caraglia,et al.  Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.

[162]  B. Viollet,et al.  Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. , 2007, Cancer research.

[163]  M. Parmar,et al.  Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). , 2007, Journal of the National Cancer Institute.

[164]  G. Caldito,et al.  Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. , 2007, Chest.

[165]  Shuzhong Zhang,et al.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.

[166]  K. Tasaka,et al.  Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. , 2007, Biochemical and biophysical research communications.

[167]  J. Barkin,et al.  Statins Reduce the Risk of Pancreatic Cancer in Humans: A Case-Control Study of Half a Million Veterans , 2007, Pancreas.

[168]  D. Miglioretti,et al.  Statin Use and Breast Cancer Risk in a Large Population-Based Setting , 2007, Cancer Epidemiology Biomarkers & Prevention.

[169]  P. Clézardin,et al.  Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. , 2007, Journal of the National Cancer Institute.

[170]  P. Coogan,et al.  Statin use and risk of colorectal cancer. , 2007 .

[171]  J. Avorn,et al.  Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly , 2006, Circulation.

[172]  P. Loehrer.  Statins and Cancer Risk: A Meta-analysis , 2007 .

[173]  M. Vidaud,et al.  Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. , 2007, Journal of hepatology.

[174]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[175]  E. Giovannucci,et al.  A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[176]  D. Kershenobich,et al.  Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus‐related liver cirrhosis , 2006, Cancer.

[177]  E. Petricoin,et al.  Breast cancer growth prevention by statins. , 2006, Cancer research.

[178]  V. Steele,et al.  Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. , 2006, Cancer research.

[179]  P. Coogan,et al.  Statin use and the Risk of Colorectal Cancer , 2006 .

[180]  A. LaCroix,et al.  Statin use and breast cancer: prospective results from the Women's Health Initiative. , 2006, Journal of the National Cancer Institute.

[181]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[182]  R. Russell,et al.  Bisphosphonates: from bench to bedside. , 2006, Annals of the New York Academy of Sciences.

[183]  A. Keeton,et al.  Insulin Enhances Growth Hormone Induction of the MEK/ERK Signaling Pathway* , 2006, Journal of Biological Chemistry.

[184]  Michael J Thun,et al.  Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. , 2006, Journal of the National Cancer Institute.

[185]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[186]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[187]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[188]  H. Welch,et al.  Statins and the Risk of Colorectal Cancer , 2005, The New England journal of medicine.

[189]  J. Olsen,et al.  Cancer risk among statin users: A population‐based cohort study , 2005, International journal of cancer.

[190]  S. Larsson,et al.  Diabetes Mellitus and Risk of Colorectal Cancer , 2005 .

[191]  M. Notarnicola,et al.  Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. , 2004, Anticancer research.

[192]  G. Thorgeirsson,et al.  Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S) , 2004, The Lancet.

[193]  Paul J. Williams,et al.  Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model , 2004, Clinical Cancer Research.

[194]  Henk-Jan Guchelaar,et al.  The risk of cancer in users of statins. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[195]  S. Heckbert,et al.  The association between 3‐hydroxy‐3‐methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women , 2004, Cancer.

[196]  H Jick,et al.  Statin use and cancer risk in the General Practice Research Database , 2004, British Journal of Cancer.

[197]  D. Gomez,et al.  Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis , 1998, Breast Cancer Research and Treatment.

[198]  C. Blomqvist,et al.  Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. , 2004, Journal of Clinical Oncology.

[199]  Katie L Stone,et al.  Lipid-lowering drug use and breast cancer in older women: a prospective study. , 2003, Journal of women's health.

[200]  JoAnn E Manson,et al.  Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. , 2003, Diabetes care.

[201]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[202]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[203]  T. Powles,et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[204]  Yuichi Sugiyama,et al.  Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.

[205]  J. Mansi,et al.  The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells , 2002, British Journal of Cancer.

[206]  A. Walker,et al.  Statin use, hyperlipidaemia, and the risk of breast cancer , 2002, British Journal of Cancer.

[207]  J. Mansi,et al.  The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells , 2002, British Journal of Cancer.

[208]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[209]  J. LeLorier,et al.  Do statins cause cancer? A meta-analysis of large randomized clinical trials. , 2001, The American journal of medicine.

[210]  X. Ding,et al.  Prevention of pancreatic cancer induction in hamsters by metformin. , 2001, Gastroenterology.

[211]  Y. Matsuzawa,et al.  Hepatocellular Carcinoma (hcc) Causes Death in Patients with Cirrhosis and Is One of the Most Prevalent Malignant Tumours Effect of Pravastatin on Survival in Patients with Advanced Hepatocellular Carcinoma. a Randomized Controlled Trial , 2022 .

[212]  F. Mach,et al.  Statins as a newly recognized type of immunomodulator , 2000, Nature Medicine.

[213]  L. Blais,et al.  3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. , 2000, Archives of internal medicine.

[214]  G. Thorgeirsson,et al.  Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. , 2000, The American journal of cardiology.

[215]  G. Pirianov,et al.  Bisphosphonates induce apoptosis in human breast cancer cell lines , 2000, British Journal of Cancer.

[216]  P. Macfarlane,et al.  The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. , 1999, The American journal of cardiology.

[217]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[218]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[219]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[220]  M. Onoda,et al.  Anti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of rats. , 1997, Carcinogenesis.

[221]  J. Willerson.  Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. , 1996, Circulation.

[222]  G. Stoner,et al.  Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatin. , 1996, Cancer letters.

[223]  W C Willett,et al.  Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.

[224]  S. Sumi,et al.  Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. , 1992, Gastroenterology.

[225]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.